Volume 24, Number 4—April 2018
CME ACTIVITY - Synopsis
Reemergence of Intravenous Drug Use as Risk Factor for Candidemia, Massachusetts, USA
Nongnooch Poowanawittayakom, Anamika Dutta, Shannon Stock, Sunkaru Touray, Richard T. Ellison, and Stuart M. Levitz
Table 4
Candida species isolated from blood of patients with candidemia at a tertiary care hospital, Massachusetts, USA, 2010–2017*
| Organisms | No. (%) patients |
p value | |
|---|---|---|---|
| IVDU, n = 24 | Non-IVDU, n = 174 | ||
| C. albicans | 7 (29.2)† | 93 (53.5) | 0.03 |
| C. glabrata | 8 (33.3) | 39 (22.4) | 0.304 |
| C. parapsilosis | 8 (33.3) | 25 (14.4) | 0.036 |
| C. tropicalis | 3 (12.5) | 13 (7.5) | 0.419 |
| C. dubliniensis | 0 | 2 (1.2) | 1.00 |
| C. guilliermondii | 0 | 1 (0.6) | 1.00 |
| C. krusei | 0 | 1 (0.6) | 1.00 |
| C. lipolytica | 0 | 1 (0.6) | 1.00 |
| C. kefyr | 0 | 1 (0.6) | 1.00 |
| Co-infected | 2 (8.3) | 2 (1.2) | 0.073 |
*IVDU, intravenous drug use.
†Percentages do not add up to 100% because patients co-infected with 2 species are counted twice.
Page created: March 16, 2018
Page updated: March 16, 2018
Page reviewed: March 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.